Management of the patient with coagulation disorders.

作者: Sunitha Govindaswamy , Jim Chandler , Ray Latimer , Alain Vuylsteke

DOI: 10.1097/00001503-200202000-00004

关键词:

摘要: Understanding normal haemostasis and the pathophysiology of its disorders is essential for providing optimal care ensuring judicious usage blood products, as keeping abreast novel therapeutic modalities in a rapidly evolving field. The growing availability synthetic coagulation factors has (at least western hemisphere) helped to reduce morbidity complications, while expanding indications these agents. Promising advances gene therapy may indeed introduce sea change next decade or two.

参考文章(67)
Norbert Lubenow, Petra Eichler, Dorothea Albrecht, Lena E Carlsson, Jürgen Kothmann, Wulf-Rüdiger Rossocha, Manfred Hahn, Henning Quitmann, Andreas Greinacher, Very Low Platelet Counts in Post-transfusion Purpura Falsely Diagnosed as Heparin-induced Thrombocytopenia: Report of Four Cases and Review of Literature Thrombosis Research. ,vol. 100, pp. 115- 125 ,(2000) , 10.1016/S0049-3848(00)00311-X
John J. Munoz, Nancy J.O. Birkmeyer, Lawrence J. Dacey, John D. Birkmeyer, David C. Charlesworth, Edward R. Johnson, Stephen J. Lahey, Mitchell Norotsky, Reed D. Quinn, Benjamin M. Westbrook, Gerald T. O’Connor, Trends in rates of reexploration for hemorrhage after coronary artery bypass surgery22The views expressed herein do not necessarily represent those of the Department of Veterans Affairs or the United States government. The Annals of Thoracic Surgery. ,vol. 68, pp. 1321- 1325 ,(1999) , 10.1016/S0003-4975(99)00728-6
Stacy S. Shord, Celeste M. Lindley, Coagulation products and their uses. American Journal of Health-system Pharmacy. ,vol. 57, pp. 1403- 1417 ,(2000) , 10.1093/AJHP/57.15.1403
C. Ménart, M. C. Trzeciak, P. Nurden, E. Fressinaud, M. Dreyfus, Y. Laurian, C. Négrier, R. d’Oiron, Use of recombinant factor VIIa in 3 patients with inherited type I Glanzmann's thrombasthenia undergoing invasive procedures. Thrombosis and Haemostasis. ,vol. 83, pp. 644- 647 ,(2000) , 10.1055/S-0037-1613884
Theodore E. Warkentin, Jo-Ann I. Sheppard, Peter Horsewood, Patricia J. Simpson, Jane C. Moore, John G. Kelton, Impact of the patient population on the risk for heparin-induced thrombocytopenia Blood. ,vol. 96, pp. 1703- 1708 ,(2000) , 10.1182/BLOOD.V96.5.1703
Flora Peyvandi, PM Mannucci, None, Rare coagulation disorders Thrombosis and Haemostasis. ,vol. 82, pp. 1207- 1214 ,(1999) , 10.1055/S-0037-1614361
Evert de Jonge, Pascale E. P. Dekkers, Abla A. Creasey, C. Erik Hack, Susan K. Paulson, Aziz Karim, Jozef Kesecioglu, Marcel Levi, Sander J. H. van Deventer, Tom van der Poll, Tissue factor pathway inhibitor dose-dependently inhibits coagulation activation without influencing the fibrinolytic and cytokine response during human endotoxemia. Blood. ,vol. 95, pp. 1124- 1129 ,(2000) , 10.1182/BLOOD.V95.4.1124.002K20_1124_1129
Y.-W. Chu, J. Korb, K. M. Sakamoto, Idiopathic thrombocytopenic purpura. Pediatrics in Review. ,vol. 21, pp. 95- 104 ,(2000) , 10.1542/PIR.21-3-95
Leonardo Kapural, Juraj Sprung, PERIOPERATIVE ANTICOAGULATION AND THROMBOLYSIS IN CONGENITAL AND ACQUIRED COAGULOPATHIES Anesthesiology Clinics of North America. ,vol. 17, pp. 923- 958 ,(1999) , 10.1016/S0889-8537(05)70140-1